Drugs / Systane PRO
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT07639034 | Nov 2025 → Feb 2026 | dry eye syndrome | Gordon Schanzlin New Vision | Completed | No outcome recorded |
| Phase 4 | NCT06975891 | May → Sep 2025 | dry eye syndrome | Scripps Poway Eyecare and Optometry | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07243275 Comparator | Feb → Sep 2026 overdue | dry eye syndrome | Indiana University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYSTANE PRO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07243275 ↗ |
| Route | Topical | “Systane Pro Topical Ophthalmic” NCT07639034 ↗ |